Basit öğe kaydını göster

dc.contributor.authorScelfo, Christina
dc.contributor.authorFrancis, Jasmine H.
dc.contributor.authorKhetan, Vikas
dc.contributor.authorJenkins, Thomas
dc.contributor.authorMarr, Brian
dc.contributor.authorAbramson, David H.
dc.contributor.authorShields, Carol L.
dc.contributor.authorPe'er, Jacob
dc.contributor.authorMunier, Francis
dc.contributor.authorBerry, Jesse
dc.contributor.authorHarbour, J. William
dc.contributor.authorYarovoy, Andrey
dc.contributor.authorLucena, Evandro
dc.contributor.authorMurray, Timothy G.
dc.contributor.authorBhagia, Pooja
dc.contributor.authorPaysse, Evelyn
dc.contributor.authorTuncer, Samuray
dc.contributor.authorChantada, Guillermo L.
dc.contributor.authorMoll, Annette C.
dc.contributor.authorUshakova, Tatiana
dc.contributor.authorPlager, David A.
dc.contributor.authorZiyovuddin, Islamov
dc.contributor.authorLeal, Carlos A.
dc.contributor.authorMaterin, Miguel A.
dc.contributor.authorJi, Xun-Da
dc.contributor.authorCursino, Jose W.
dc.contributor.authorPolania, Rodrigo
dc.contributor.authorKiratli, Hayyam
dc.contributor.authorAll-Ericsson, Charlotta
dc.contributor.authorKebudi, Rejin
dc.contributor.authorHonavar, Santosh G.
dc.contributor.authorVishnevskia-Dai, Vicktoria
dc.contributor.authorEpelman, Sidnel
dc.contributor.authorDaniels, Anthony B.
dc.contributor.authorLing, Jeanie D.
dc.contributor.authorTraore, Fousseyni
dc.contributor.authorRamirez-Ortiz, Marco A.
dc.date.accessioned2019-12-12T06:45:29Z
dc.date.available2019-12-12T06:45:29Z
dc.date.issued2017
dc.identifier.issn2222-3959
dc.identifier.urihttps://doi.org/10.18240/ijo.2017.06.20
dc.identifier.urihttp://hdl.handle.net/11655/16941
dc.description.abstractAIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children's Hospital of Los Angeles (CHLA) version, 33% used the Children's Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.
dc.language.isoen
dc.publisherIjo Press
dc.relation.isversionof10.18240/ijo.2017.06.20
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOphthalmology
dc.titleAn International Survey of Classification and Treatment Choices For Group D Retinoblastoma
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalInternational Journal Of Ophthalmology
dc.contributor.departmentGöz Hastalıkları
dc.identifier.volume10
dc.identifier.issue6
dc.identifier.startpage961
dc.identifier.endpage967
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster